Clinical Trial Update: Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL [Phase 2]

View source ↗

Summary

Phase 2 study of AT13387 (Onalespib) in ALK+ anaplastic large cell lymphoma, mantle cell lymphoma, and BCL-6+ diffuse large B-cell lymphoma was terminated; resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Diffuse Large B-cell Lymphoma
• Mantle Cell Lymphoma
• Transformed Non-hodgkin Lymphoma

Drugs mentioned

• AT13387 (Onalespib) (onalespib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Anaplastic Large Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2022-09-13